8th Annual ENETS Conference

for the

*Diagnosis and Treatment of Neuroendocrine Tumor Disease*

9-11 March 2011
Lisbon • Portugal
The ENETS Executive Committee welcomes you to its 8th Annual Conference and also to Lisbon. In attending this premier global event, you join some of the most respected and dynamic researchers and key opinion leaders in the field of neuroendocrine tumor research and multidisciplinary management of the disease. Over the next two days, these expert specialists will be sharing the most cutting-edge research in the field today.

The European Neuroendocrine Tumor Society today claims close to 800 members located in 50 countries. We consider this a notable achievement for an organization dedicated to a rare disease. Moreover, attendance at our annual conferences continues to increase, with nearly 300 more participants registering than planned. Again, I welcome everyone to our annual meeting and appreciate the distances traveled to be here.

While our 2010 conference in Berlin drew positive feedback, the ENETS Executive Committee considered requests to expand the scientific program for this year’s conference. This year’s conference, for the first time, includes a postgraduate conference, which, once announced, quickly attracted interest and participation. We also offer this year a study nurses meeting. As well, back by popular demand is the ‘Meet the Professor’ sessions, and we added an additional one to the four previously offered. Lectures encompass imaging, MEN-1, metastatic liver, pancreatic surgery and gastrinoma. Finally, the Society offered again 10 travel grants to young researchers, a practice we established in 2010 and look forward to continuing.

I am exceptionally proud to announce that we received 172 abstracts for the conference, the most ever submitted. The growth in NET research, as well as the continued increase in membership registrations and abstract submissions, is encouraging.

The ENETS Annual Conference this year is sponsored by the pharmaceutical firms Novartis, as platinum sponsor; Pfizer, as gold sponsor; Ipsen, as silver sponsor; and Covidien and Sirtex as bronze sponsors. We thank them for their generous support. We also welcome Biomedica Life Sciences, CISBIO Bioassays, ITG Isotope Technologies, and Keocyt, all of which are exhibiting during the conference.

Philippe Ruszniewski, M.D., Ph.D. Clichy, France
Chairman, European Neuroendocrine Tumor Society (ENETS)
**Wednesday, 9 March 2011**

<table>
<thead>
<tr>
<th>9:45 - 17:45</th>
<th>ENETS POST-GRADUATE COURSE</th>
<th>Auditorio II</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00</td>
<td>Welcome Reception</td>
<td>Pavilion IV</td>
</tr>
</tbody>
</table>

**Thursday, 10 March 2011**

**7:30 - 8:30**  
Meet the Professor:  
(Ticketed sessions; Prior registration and payment required.)

- **Imaging NETs: Current imaging standards and new developments**  
  M.-P. Vullierme, Clichy, FRA  
  Sala 1.02
- **MEN-1**  
  M.-L. Brandi, Florence, ITA  
  Sala 1.03

<table>
<thead>
<tr>
<th>8:00 - 9:00</th>
<th>Conference Registration</th>
</tr>
</thead>
</table>
| 9:00 - 9:15 | Welcome and Introduction  
  P. Ruszniewski, Clichy, France |

<table>
<thead>
<tr>
<th>9:15 - 10:45</th>
<th>Session 1: Global perspectives on epidemiology, national considerations and classification</th>
</tr>
</thead>
</table>
  B. Maples, Ponte Vedra Beach, FL, USA |
| 9:15 - 9:20  | Spain  
  R. Garcia Carbonero, Sevilla, ESP |
| 9:20 - 9:25  | USA  
  B. Maples, Ponte Vedra Beach, FL, USA |
| 9:25 - 9:30  | Japan  
  T. Ito, Fukuoka, JAP |
| 9:30 - 9:35  | India  
  P. Jagannath, Mumbai, IND |
| 9:35 - 9:40  | Brazil  
  R. Younes, São Paulo, BRA |
| 9:40 - 10:00 | Classification of GEP-NETs on a transatlantic scale  
  L. Tang, New York, NY, USA; G. Rindi, Rome, ITA |
| 10:00 - 10:10 | Epidemiology: A global perspective  
  D. O’Toole, Dublin, IRL |
| 10:10 - 10:40 | Toward better diagnosis and treatment: Updated ENETS Guidelines  
  P. Ruszniewski, Clichy, France |
| 10:40 - 10:45 | Summary  
  G. Klöppel, Munich, GER |

| 10:45 - 11:15 | 2011 ENETS Life Achievement Award  
  Recipient: J. Rehfeld, Copenhagen, DEN  
  Chair: P. Ruszniewski, Clichy, FRA  
  Dedication: K. Öberg, Uppsala, SWE |

| 11:15 - 11:45 | COFFEE BREAK and POSTER VIEWING |

| 11:45 - 12:30 | SELECTED ABSTRACTS: Basic science related to cancer biology  
  Chair: A. Perren, Bern, SUI |
|---------------|--------------------------------------------------------------------------------|
| 11:45 - 12:00 | The global mTOR inhibitor Torin1 is more effective than the mTORC1 inhibitor, Everolimus, alone or in combination with histone deacetylases inhibitors in suppressing NET cell proliferation  
  S. Grozinsky-Glasberg, Tel Aviv, ISR |
| 12:00 - 12:15 | Cell cycle phase expression profile guided selection of proliferative markers for well-differentiated small intestinal neuroendocrine neoplasms  
  M. Kidd, New Haven, CT, USA |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:15 - 12:30 | Changes on chromosome 18 are involved in sporadic and familial ileal carcinoid tumor development  
  E. Tiensuu Janson, Uppsala, SWE |
| 12:30 - 14:30 | LUNCH and NOVARTIS SYMPOSIUM  
  Clinical Advancements in NET: Optimize Outcomes by Personalizing Therapy  
  Auditorio I |
| 14:30 - 16:00 | SESSION 2: ENETS Tumor Board – Discussion of clinical cases  
  Chairs:  
  G. Delle Fave, Rome, ITA  
  E. P. Krenning, Rotterdam, NED  
  Tumor board:  
  D. Bartsch, Marburg, GER  
  B. Kos-Kudła, Katowice, POL  
  C. Lombard-Bohas, Lyon, FRA  
  G. Paganelli, Milan, ITA  
  M. Papotti, Turin, ITA  
  J. Ramage, Basingstoke, GBR  
  A. Sundin, Stockholm, SWE  
  14:30 - 15:00 | Metastatic well-differentiated pancreatic NET  
  E. Van Cutsem, Leuven, BEL |
| 15:00 - 15:30 | Liver NET without primary  
  E. Baudin, Villejuif, FRA |
| 15:30 - 16:00 | Metastatic midgut  
  D. Gross, Jerusalem, ISR |
| 16:00 - 16:45 | SELECTED ABSTRACTS: Clinical Research  
  Chair:  
  W. de Herder, Rotterdam, NED  
  16:00 - 16:15 | Tumor size correlates with malignancy in non-functioning pancreatic endocrine tumors  
  S. Partelli, Verona, ITA |
| 16:15 - 16:30 | Hepatic arterial embolization v. chemoembolization in patients with liver metastases of digestive NETs  
  TBA |
| 16:30 - 16:45 | Risk of metastatic spread in patients with early-stage, surgically resected pancreatic NETs  
  J. Strosberg, Tampa, FL, USA |
| 16:45 - 18:05 | SESSION 3: Difficult management problems in symptomatic NET  
  Chairs:  
  B. Kos-Kudła, Katowice, POL  
  E. Tiensuu Janson, Uppsala, SWE  
  16:45 - 17:05 | Refractory carcinoid syndrome  
  U.-F. Pape, Berlin, GER |
| 17:05 - 17:25 | Refractory hypoglycemia  
  B. Eriksson, Uppsala, SWE |
| 17:25 - 17:45 | Ectopic ACTH syndrome  
  J. Newell-Price, Sheffield, GBR |
| 17:45 - 18:05 | Carcinoid heart disease  
  J. Davar, London, GBR |
| 18:15 - 19:00 | ENETS General Assembly  
  Auditorio II |
Friday, 11 March 2011

7:30 - 8:30  Meet the Professor:
(Ticketed sessions; Prior registration and payment required.)
Targeting metastatic liver (ablative therapy)
J.-P. Pelage, Boulogne, FRA Sala 1.02
T. Kröncke, Berlin, GER Sala 1.02
Current issues in pancreatic surgery
M. Falconi, Verona, ITA Sala 1.03
U. Knigge, Copenhagen, DEN Sala 1.03
Gastrinoma
R. Jensen, Bethesda, MD, USA Sala 1.13

8:30 - 9:30  Session 4: Recent advances in basic science applicable to NET disease
Chairs:  G. Rindi, Rome, ITA
        M. Alison, London, GBR
8:30 – 8:50  Cancer stem cells
            M. Alison, London, GBR
8:50 – 9:10  Angiogenesis and cancer
            J.-Y. Scoazec, Lyon, FRA
9:10 – 9:30  Metabolic re-programming and malignant progression
            T. Cramer, Berlin, GER

9:30 – 10:10  SESSION 5: Biomarkers – Lessons from other cancers
Chair:  K. Öberg, Uppsala, SWE
9:30 – 9:40  Introduction
            K. Öberg, Uppsala, SWE
9:40 – 9:55  Pancreatic cancer
            M. Hidalgo, Madrid, ESP
9:55 – 10:10  Colorectal cancer
               A. Roth, Geneva, SUI

10:10 – 10:30  2010 ENETS Translational Medicine Fellowship presentation
(co-sponsored by Ipsen)
C. De Martino, Naples, ITA
2011 Young Investigator Awards

10:30 – 11:30  SESSION 6: Critical review of current non-surgical treatment –
efficacy, side effects, cost-effectiveness and quality of life
Chairs:  M. Kulke, Boston, MA, USA
        B. Taal, Amsterdam, NED
10:30 – 10:50  Medical treatment
               M. Pavel, Berlin, GER
10:50 – 11:05  Locoablative treatment
               R. Salazar, Barcelona, ESP
11:05 – 11:20  PRRT
               D. Kwekkeboom, Rotterdam, NED
11:20 – 11:30  Wrap-up
               U.-F. Pape, Berlin, GER

11:30 – 11:55  COFFEE BREAK and POSTER VIEWING
Friday, 11 March 2011

11:55 – 13:15 SESSION 7: Bronchial carcinoids – Similarities and differences to GEP-NETs
Chairs: M. Caplin, London, GBR
W. Travis, New York, NY, USA

11:55 – 12:10 Histopathology and epidemiology
W. Travis, New York, NY, USA

12:10 – 12:25 Clinical presentation and investigations
C. Toumpanakis, London, GBR

12:25 – 12:40 Medical treatment
P. Ferolla, Perugia, ITA

12:40 – 12:55 Surgery
H. Asamura, Tokyo, JAP

12:55 – 13:15 Discussion and wrap-up
M. Caplin, London, GBR

13:15 – 15:15 LUNCH and PFIZER & IPSEN SYMPOSIUM
Moving towards a new era in the treatment of GEP-NET
Auditorio I

15:15 – 16:00 SESSION 8: Top news in NETs, 2010-2011
Chairs: G. Kaltsas, Athens, GRE
R. Thakker, Oxford, GBR

15:15 – 15:30 Basic science
I. Modlin, New Haven, CT, USA

15:30 – 15:45 Clinical pancreas and duodenum
G. Cadiot, Reims, FRA

15:45 – 16:00 Clinical small and large bowel
W. de Herder, Rotterdam, NED

16:00 – 16:15 Conclusion
P. Ruszniewski, Clichy, FRA
The titles of all accepted abstracts, along with first authors, are listed here:

**BASIC SCIENCE RELATED TO CANCER BIOLOGY**

(B1) Chromogranin B is a Prognostic Marker in NETs  
P. Bech, London, GBR

(B2) A Proteomic Approach Identifies Novel Proteins Involved in Invasion Mechanisms in Enteroendocrine Carcinomas  
C. Couderc, Lyon, FRA

(B3) Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors  
T. Cui, Uppsala, SWE

(B4) Expression of IGF/mTOR Pathway Components in Human Pheochromocytomas and In Vitro Inhibition of PC12 Rat Pheochromocytoma Cell Growth by mTOR Inhibitors  
M.C. De Martino, Rotterdam, NED

(B5) A Novel Missense Mutation of the TMEM127 Gene that Leads to Pheochromocytoma Phenotype  
R. Domingues, Lisbon, POR

(B6) The Succinate Dehydrogenase Genetic Testing in Patients with Extra-adrenal Paragangliomas: The Portuguese Cancer Center (Lisboa) Experience  
R. Domingues, Lisbon, POR

(B7) Utilization of Gene Network Graph Topology with Inference Relevance Analysis Delineates G Protein-coupled Receptor Pathways and CREB Targets in Small Intestinal Neuroendocrine Neoplasia  
I. Drozdov, London, GBR

(B8) Morbidity and Mortality Associated with Desmoplasia in Midgut Neuroendocrine Tumors (NETs)  
F. El-Khouly, London, GBR

(B9) Challenges in the Management of VIPoma Patients  
F. El-Khouly, London, GBR

(B10) The Global mTOR Inhibitor Torin1 is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylases Inhibitors, in Suppressing Neuroendocrine Tumors Cell Proliferation  
S. Grozinsky-Glasberg, Tel Aviv, ISR

(B11) CK 19 Expression in Pancreatic Neuroendocrine Tumors as Negative Prognostic Factor and a Risk Factor for Metastases  
L. Gurevich, Moscow, RUS

(B12) Glycodelin Expression in Pancreatic Neuroendocrine and Solid-Pseudopapillary Tumors as an Important Factor of Favorable Disease Prognosis  
L. Gurevich, Moscow, RUS

(B13) Expression of EGFR and IGF Pathway Genes in Insulinomas  
M. Henfling, Maastricht, NED

(B14) Transcription Factor Signature in Pancreatic and Duodenal Neuroendocrine Neoplasms  
G. Hermann, Zenfin, ISR

(B15) Neuroendocrine Tumors - Imaging Abdominal Complications  
J. Ip, Lisbon, POR

(B16) Chromogranin A as a Predictor of Progression, Regression or Stable Disease in Ileo-Cecal Neuroendocrine Tumors  
K. Jensen, Copenhagen, DEN

(B17) Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target  
G. Kanakis, Athens, GRE

(B18) Evidence for the role of miR196a in regulating Small Intestinal Neuroendocrine Tumor Proliferation and Metastasis via HOX/AKT Pathway Activation  
M. Kidd, New Haven, CT, USA

(B19) Differential Protein Expression in Small Intestinal Carcinoids and Liver Metastases  
M. Kim, New York, NY, USA

(B20) Cell Cycle Phase Expression Profile Guided Selection of Proliferative Markers for Well-differentiated Small Intestinal Neuroendocrine Neoplasms  
B. Lawrence, New Haven, CT, USA

(B21) Novel Insights in Octreotide Effects on Human Neuroendocrine Cell Line CNDT2.5  
S.C. Li, Uppsala, SWE
(B22) Genome-Wide MicroRNA Expression in Small Intestine Neuroendocrine Tumors (“Midgut carcinoids”): Upregulation of miRNA-182, miRNA-183 and Downregulation of miRNA-215
S.C. Li, Uppsala, SWE

(B23) Clinical and Immunohistochemical Evaluation of Medullary Thyroid Cancer (MTC) and C Cell Hyperplasia (CCH)
F. Lugli, Rome, ITA

(B24) Results of Resection and Predictors of Outcome of Pancreatic Neuroendocrine Tumors
R. Marudanayagam, London, GBR

(B25) A Novel PKCII Inhibitor Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells
D. Molè, Ferrara, ITA

(B26) Localization of Sporadic Neuroendocrine Tumors by Gene Expression Analysis of Their Metastases
N. Posorski, Jena, GER

(B27) Plasma Somatostatin: Gastrin Ratio Improves the Diagnosis of Gastrinoma
R. Ramachandran, London, GBR

(B28) Mammalian Target of Rapamycin Pathway Activation is Associated with RET Mutation Status in Medullary Thyroid Carcinoma
I. Rapa, Turin, ITA

(B29) Loss of Expression of the DNA Mismatch Repair Proteins MLH1 and MSH2 is Rare in Pancreatic and Small Intestinal Neuroendocrine Tumors
D. Rayson, Halifax, CAN

(B30) The Immunohistochemical (IHC) Expression and Prognostic Value of ER, PR, and HER2/neu in Pancreatic and Small Intestinal Neuroendocrine Tumors
D. Rayson, Halifax, CAN

(B31) Insulin-like Growth Factor-1 Receptor (IGF-1R) and its Inhibition in Non-functioning Neuroendocrine Tumors
H. Sasano, Sendai, JAP

(B32) The Utility of Alpha Internexin as a Predictive Tissue Biomarker for Proliferation in Gastrointestinal and Pancreatic Neuroendocrine Tumors
S. Schimmack, Heidelberg, GER

(B33) SDHB Loss Predicts Malignancy in Pheochromocytomas/Sympathetic Parangangiomas, but Not Through Hypoxia Signalling
A. Schmitt, Bern, SUI

(B34) Microvessel Density and Prognosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
C. Soares, Porto, POR

(B35) Role of VEGFR-2, P53, P53R2 and Ki-67 Expression in Metastatic Carcinoid Cancer
R. Spencer, São Paulo, BRA

(B36) Hepatic Neuroendocrine Tumor Metastasis Proliferation is Hepatocyte Regulated Via a 5HT7 Mediated Induction of an IGF 1 and HGF Feedback Loop Mediated by cAMP, PKA-independent pAKT and pCREB
B. Svejda, New Haven, CT, USA

(B37) Reduced MEN1 Gene Expression in Pulmonary Carcinoids Is Associated With Metastatic Disease
D. Swarts, Maasricht, NED

(B38) Integrated Genome-Wide DNA Methylation and mRNA Expression Analysis of Pancreatic NETs Identifies Differential Activation of the Hypoxia Inducible Factor (HIF) Pathway Between Low and Intermediate Grade Tumors
C. Thirlwell, London, GBR

CLINICAL RESEARCH

(C1) Nurse Evaluation of Long-acting Somatostatin Analogue Injection Devices: A Quantitative Study
D. Adelman, Chicago, IL, USA

(C2) Dissociation Between Iodine-131 meta-iobenzylguanidine (MIBG) Scintigraphy and Radiolabeled Octreotide in the Localization and Management of Sporadic Malignant Pheochromocytoma: An Impact on Management
M. Ahmed, Riyadh, SAU

(C3) A Variant Pancreatic Insulinoma in MEN1 Syndrome Characterized by Normoglycemia/Normoinsulinemia but Abnormal C-Peptide and Abnormal Proinsulin Levels
M. Ahmed, Riyadh, SAU

(C4) Diagnosis and Management of Thymic Neuroendocrine Tumors: A Case Series Review
E.M. Akay, London, GBR

(C5) New Imaging Modalities in the Diagnosis of Phaeochromocytoma
A. Amin, London, GBR

(C6) The Risk of Metachronous Cancers In Patients with Small Intestinal Carcinoid Tumors
S. Amin, New York, NY, USA
(C7) Efficacy and Safety of the Combination Streptozotocin, 5-FU in Endocrine Pancreatic Tumors: A Retrospective Study
P. Antonodimitrakis, Uppsala, SWE

(C8) Magnetic Resonance Imaging (MRI) v. Endoscopic Ultrasonography (EUS) for the Detection of ≥10-mm Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1 (MEN1). A GTE Study
C. Barbe, Reims, FRA

(C9) Czech Neuroendocrine Registry - First Results
J. Barkmanova, Prague, CZE

(C10) Somatostatin Analogues as a Therapeutic Option in a Series of 91 Patients with Gastric Carcinoids
C. Basagiannis, Athens, GRE

(C11) Effect of Everolimus + Octreotide LAR Treatment on 5-Hydroxyindoleacetic Acid Levels in Patients With Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results
E. Baudin, Villejuif, FRA

(C12) Tumor Size Correlates With Malignancy in Non-Functioning Pancreatic Endocrine Tumor
R. Bettini, Negrar, ITA

(C13) Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
A. Bianchi, Rome, ITA

(C14) Matrix metalloproteinases (MMPs) and Tissue Inhibitors of Matrix Metalloproteinases (TIMPs) in GEP-NET Patients – A Potential Prognostic Biomarker for Metastases
J. Blicharz-Dorniak, Katowice, POL

(C15) Management of Insulinomas: Perioperative and Long-term Outcomes Following Enucleations and Pancreatic Resections in 198 Patients
L. Boninsegna, Verona, ITA

(C16) Clinical Characteristics of the 5,160 Patients Included in the French Database of the French Endocrine Tumor Group (GTE)
F. Borson-Chazot, Lyon, FRA

(C17) Treatment of Pancreatic Neuroendocrine Neoplasms: Data from a Prospective Observational Multicenter Study
V. Capitanio, Milan, ITA

(C18) Primary Renal Somatostatinoma with Hepatic Metastases
R.W. Carroll, London, GBR

(C19) The Use of Guar Gum in the Medical Management of Hyperinsulinaemic Hypoglycaemia
R.W. Carroll, London, GBR

(C20) Primary Lymph Node Gastrinoma: A Genuine Entity? Two Case Reports and a Review of the Literature
R.W. Carroll, London, GBR

(C21) Lutetium-177 DOTATATE Therapy in the Management of Neuroendocrine Tumors
R.W. Carroll, London, GBR

(C22) Gallium-68 DOTATATE PET CT Frequently Changes Patient Management or Staging When Compared with Indium-111 Octreotide in the Assessment of Neuroendocrine Tumors
R.W. Carroll, London, GBR

(C23) Sorafenib and Bevacizumab Combination Targeted Therapy in Advanced Neuroendocrine Tumor: A Phase II Study of the Spanish Neuroendocrine Tumor Group (GETNE0801)
D. Castellano, Madrid, ESP

(C24) Afinitor UK Particular Patient Supplies for Advanced Neuroendocrine Tumors (NETs)
J. Chambers, Frimley, GBR

(C25) Risk of Cardiovascular Events (CV) in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
C.C. Chen, Plymouth Meeting, PA, USA

(C26) Alterations of TIMP-3 Gene in Insulinomas and Its Significance
Y.J. Chen, Beijing, CHI

(C27) Characteristics of Patients with Well-differentiated Metastatic Lung Neuroendocrine Tumors
C. Chougnet, Villejuif, FRA

(C28) Well-differentiated Pancreatic Neuroendocrine Tumor of Uncertain Behavior: A Case Report
J. Couto, Porto, POR

(C29) Carcinoid Metastases to the Breast: More Common than Previously Thought. A Presentation of 13 Cases
J. Crona, Uppsala, SWE

(C30) Insulinoma: A Rare Tumor?
V. Daraki, Heraklion, GRE
(C31) Coexistence of a Somatostatin-Producing Carcinoma of Duodenum and a Jejuna Gastrointestinal Stromal Tumor (GIST) in a Patient with Von Recklinghausen’s Disease
V. Daraki, Heraklion, GRE

(C32) Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs
M.C. De Martino, Villejuif, FRA

(C33) Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
T.E. Delea, Brookline, MA, USA

(C34) Ki-67 (MIB-1) Proliferative Activity and Beta-Catenin Immunorepression in Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumors
V. Delektorskaya, Moscow, RUS

(C35) Evaluation of the Association Between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
P. Den Gupta, London, GBR

(C36) Carcinoid
M. Derylo, Cleveland, OH, USA

(C37) Clinical Case of ACTH-secreting Thymic Carcinoma with Multiple Metastases to the Brain, Ovary and Skin
A. Drevai, Moscow, RUS

(C38) Diagnostic Algorithm of Pancreatic Neuroendocrine Tumors
A. Egorov, Moscow, RUS

(C39) Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
M. Fekih, Villejuif, FRA

(C40) Complete Remission in a Patient with Metastatic Type 1 Gastric Carcinoid (GCA1) Treated with a Long-acting Somatostatin Analogue
M. Fraenkel, Jerusalem, ISR

(C41) Immunohistochemical Analysis of Epithelial-Mesenchymal Transition Markers in Neuroendocrine Tumors of the Lung
J.A. Galván, Oviedo, ESP

(C42) Treatment with 177Lutetium-DOTA-Tyr3-octreotate in Patients with Neuroendocrine Tumors
D. Granberg, Uppsala, SWE

(C43) Patients Treated for Well-Differentiated Neuroendocrine Tumors: A Study to Evaluate the Ratio of Patients Lost to Follow-up
R. Guimbaud, Toulouse, FRA

(C44) A Case of Primary Hepatic Carcinoid Tumor Misdiagnosed as Hepatocellular Carcinoma (HCC)
J. Hazrati, Urmia, IRN

(C45) Risk of Hepatic and Gastrointestinal (GI) Events in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
G.P. Hess, Plymouth Meeting, PA, USA

(C46) Goblet Cell Carcinoid Tumors - A Retrospective Study of Clinical Presentation and Survival
N. Holt, Aarhus, DEN

(C47) Treatment and Prognosis of Patients with Poorly Differentiated Neuroendocrine Tumors
N. Holt, Aarhus, DEN

(C48) An Observational Registry Collecting Data on Gastroenteropancreatic Neuroendocrine Tumor Patients (GEP-NET Registry) in the Middle East and Asia
T.L. Hwang, Taoyuan, TWN

(C49) Pancreatic Metastases from Bronchopulmonary Atypical Carcinoid: An Uncommon Tumor Spreading to a Rare Location
D. Iacovazzo, Rome, ITA

(C50) Overall Survival (OS) Analysis of Sunitinib (SU) After Adjustment for Crossover (CO) in Patients With Pancreatic Neuroendocrine Tumors (NET)
J. Ishak, Dorval, CAN

(C51) One-year Response to Everolimus in a Case of Advanced Pancreatic NET
P. Jiménez Fonseca, Oviedo, ESP

(C52) Description and Treatment of GEP NETs in a Spanish Hospital During 10 Years
P. Jiménez Fonseca, Oviedo, ESP

(C53) Doxorubicin, Etoposide and Cisplatin as First-line Treatment in Advanced Adrenocortical Carcinoma
P. Jiménez Fonseca, Oviedo, ESP

(C54) A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
V. Johanson, Gothenburg, SWE

(C55) Metastatic Gastrinoma Co-secreting PTHrP and ACTH
J. Joharatnam, London, GBR
(C56) Paraganglioma: Gallium-68 DOTOTATE PET CT Scanning, a Useful Addition to MIBG Scanning in Metastatic Disease
J. Joharatnam, London, GBR

(C57) Radio Guided Surgery in Neuroendocrine Tumors Using 68Ga-Labeled Somatostatin Analogs – A Pilot Study
D. Kaemmerer, Bad Berka, GER

(C58) UMB-4 as New Monoclonal Somatostatin Receptor Antibody: Correlation of Immunostaining with Molecular Imaging Using Somatostatin Receptor PET/CT
D. Kaemmerer, Bad Berka, GER

(C59) Occurrence of Other Primary Malignancies in Patients with Endocrine Tumors of the Digestive Tract and Pancreas
K. Kamp, Rotterdam, NED

(C60) Circulating Tumor Cells (CTCs) Correlate with Overall Survival in Neuroendocrine Tumors (NETs)
M.S. Khan, London, GBR

(C61) Ki-67 is a Better Prognostic Marker than Mitotic Count in Neuroendocrine Tumors
M.S. Khan, London, GBR

(C62) Y90-DOTATATE in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Survival Following Different Indications for Treatment
M.S. Khan, London, GBR

(C63) Long-term Follow-up of Tissue Valve Prostheses in Carcinoid Heart Disease
D. Knight, London, GBR

(C64) Diverging Incidence and Survival Trends for Neuroendocrine Tumors due to Histological Grade
C.M. Korse, Amsterdam, NED

(C65) Robot-assisted Distal Pancreatectomy for Insulinoma. A Case Report
A. Kriger, Moscow, RUS

(C66) Extreme Obesity Due to Insulinoma Within Multiple Endocrine Neoplasia (MEN) 1 Syndrome
I. Kruljac, Zagreb, HRV

(C67) Relationship Between Dose and Molecular Response After Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumors: Preliminary Results
H. Kulkarni, Bad Berka, GER

(C68) Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
C. Lambertini, Basel, SUI

(C69) PCR Assessment of Carcinoid Lymph Node Metastasis CgA Transcript Outperforms Immunostaining, Tyramide Signal Amplification and H&E and Significantly Upstages Disease
B. Lawrence, New Haven, CT, USA

(C70) The SEER as a Prophet: Epidemiological Analysis as a Harbinger of Evolving Priorities in Gastroenteropancreatic Neuroendocrine Neoplasia
B. Lawrence, New Haven, CT, USA

(C71) Temozolomide in Metastatic Bronchial Carcinoids
D. Lindholm, Uppsala, SWE

(C72) Biochemical Markers in Diagnosis and Monitoring of Neuroendocrine Tumors
N. Lyubimova, Moscow, RUS

(C73) Hepatic Arterial Embolization v. Chemoembolization in Patients with Liver Metastases of Digestive Neuroendocrine Tumors
F. Maire, Clichy, FRA

(C74) Difficulties in Differential Diagnostics of Neuroendocrine Tumors
A. Markovich, Moscow, RUS

(C75) Prognostic Factors and Survival in 481 Patients with Pancreatic and Peripancreatic Endocrine Tumors: Results from the National Cancer Registry of Spain (RGETNE)
E. Martin-Perez, Madrid, ESP

(C76) Pancreatic Endocrine Tumors: TNM staging and WHO Grading Relation with Prognosis
R.G. Martins, Porto, POR

(C77) Chronic Atrophic Gastritis Associated with Hyperparathyroidism: A Prospective Study
S. Massironi, Milan, ITA

(C78) Risk Stratification Using Octreotide Test for Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results of Prospective Validation of the Test
S. Massironi, Milan, ITA
(C79) Everolimus Reduces Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
M. Minoia, Ferrara, ITA

(C80) Early Detection of Gastric GIST Tumor in a Patient with Rectal Neuroendocrine Cancer – A Case Report
S. Mucha, Lodz, POL

(C81) Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) v. Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Results
K. Oberg, Uppsala, SWE

(C82) Report of Two First-Degree Relatives with Appendix Carcinoid and Review of the Literature
J. O’Connor, Buenos Aires, ARG

T. Okusaka, Tokyo, JAP

(C84) Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
I.H. Olsen, Copenhagen, DEN

(C85) Predictive Factors of Tumor Control in Patients with Well-differentiated Digestive Endocrine Carcinomas (WDEC) Treated with Lanreotide
M. Palazzo, Clichy, FRA

(C86) Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)
M. Pavel, Berlin, GER

(C87) Immunohistochemical Expression of Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors Using IRS- and Her2-scoring Scheme
L. Peter, Jena, GER

(C88) Effect of mTOR Inhibitor and Octreotide LAR on the Vascularization of Hepatic Metastases of Non-Pancreatic NETs: Preliminary Semi-Quantitative Dynamic MRI Assessment
C.T. Pham, Villejuif, FRA

(C89) Four-year Follow-up in a Case of Gastric Neuroendocrine Carcinoma
C. Poiana, Bucharest, ROM

(C90) Aggressive Somatostatinoma, with Associated Pheochromocytoma in a Neurofibromatosis Patient
C. Poiana, Bucharest, ROM

(C91) Very Long-term Follow-up (> 5 years) of Renal Function of Neuroendocrine Tumor Patients Treated with Five or More Cycles of Peptide Receptor Radionuclide Therapy (PRRNT)
Prasad V, Bad Berka, GER

(C92) Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe?
Prasad V, Bad Berka, GER

(C93) Ga-68 SMS-R PET/CT in the Detection of Unknown Primary Neuroendocrine Tumor- Single Centre Result in 124 Patients
V. Prasad, Bad Berka, GER

(C94) Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumors (NETs)
E. Raymond, Clichy, FRA

(C95) An Unexpected Diagnosis
A. Rebellato, Padova, ITA

(C96) Long-term Survival and Quality of Life in Patients with ileum NET: A Single Center Experience
A. Reincke, Munich-Großhadern, GER

(C97) Distinct Cut-Off Values of Ki-67-index for NET-Grading in a Large German Multicenter Cohort
A. Rinke, Marburg, GER

(C98) Liver and Liver-Pancreas Transplantation in the Two-stage Treatment of Liver Metastasized Neuroendocrine Tumors of the Pancreas: About Three Cases
G. Roeyen, Edegem, BEL

(C99) Plasma Chromogranin A in Patients with MEN I and Pancreatic Endocrine Tumors
R.E. Rossi, Milan, ITA

(C100) Aberrant Expression of FSH Receptor in Pancreatic Neuroendocrine Tumors
D. Russo, Pisa, ITA

(C101) Successful Endoscopic Ultrasound-Guided Alcoholic Ablation of Insulinoma
C. Schnack, Odense, DEN
(C102) Surgical Treatment of Non-functioning Neuroendocrine Tumors of the Pancreas
V. Shkarban, Kiev, UKR

(C103) Focal Nesidioblastosis in an Adult
T. Simsek, Kocaeli, TUR

(C104) Laparoscopic v. Open Resection of Pancreatic Endocrine Neoplasms: A Review
M. Solovy, Lviv, UKR

(C105) Prognostic Features in Patients with Metastatic Neuroendocrine Tumor Undergoing Y-90 Embolization
S. Soltman, New York, NY, USA

(C106) The Impact of 68Ga-DOTATOC PET/CT on the Multimodal Management of Patients with Neuroendocrine Tumors
G. Sotropoulos, Essen, GER

(C107) Peptide Receptor Radiotherapy as a Potential Tool of Neoadjuvant Therapy in Patients with Inoperable Neuroendocrine Tumors (NETs)
A. Sowa-Staszczak, Krakow, POL

(C108) 99mTc Labelled GLP-1 Scintigraphy with Use of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-Exendin-4 in the Diagnosis of Insulinoma
A. Sowa-Staszczak, Krakow, POL

(C109) Unusual Behavior of Gastric Carcinoid Type 1
M.P. Spampatti, Milan, ITA

(C110) Swiss Neuroendocrine Tumor (SwissNET) Registry: Results After 30 Months
C. Stettler, Bern, SUI

(C111) Phase II Study of Sunitinib Following Hepatic Transarterial Embolization for Metastatic Neuroendocrine Tumors
J. Strosberg, Tampa, FL, USA

(C112) Comparison of the AJCC and ENETS Staging Classifications for Neuroendocrine Tumors of the Pancreas
J. Strosberg, Tampa, FL, USA

(C113) Risk of Metastatic Spread in Patients with Early-Stage, Surgically Resected Pancreatic Neuroendocrine Tumors
J. Strosberg, Tampa, FL, USA

(C114) Survival Analyses of Pancreatic Neuroendocrine Tumors: Contrasting Institutional Databases with Population-Based Registries
J. Strosberg, Tampa, FL, USA

(C115) Changes on Chromosome 18 are Involved in Sporadic and Familial Ileal Carcinoid Tumor Development
E. Tiensuu Janson, Uppsala, SWE

(C116) Comparison of 18F-DOPA, 68Ga-Somatostatin Analogues and 18F-FDG PET-CT in Patients with Recurrent Medullary Thyroid Carcinoma
G. Treglia, Rome, ITA

(C117) Sporadic Hypercalcitoninemia: Thyroid Medullary Carcinoma, Autoimmune Thyroiditis or GLP-1 Agonists, Effect?
R. Trifanescu, Bucharest, ROM

(C118) Dosimetry with 111In-Octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC
S. Van Binnebeek, Leuven, BEL

(C119) Management of Patients with Multiple Pancreatic Tumors
I. Vasiliev, Moscow, RUS

(C120) Pancreatic Neuroendocrine Tumors: Experience of Endocrinology Department of the University Hospital of Coimbra
A. Vieira, Coimbra, POR

(C121) Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy
S. Welin, Uppsala, SWE

(C122) The Carcinoid Syndrome Caused by Retroperitoneal Carcinoid Tumors
B. Wilson, Odense, DEN

(C123) Recognizing Carcinoid Heart Disease and Timing of Cardiac and Abdominal Procedures
J. Zacks, New York, NY, USA

(C124) Long-term Results and Life Quality in Patients with Pancreatic Neuroendocrine Tumors at Munich University-Großhadern
S. Zahn, Munich-Großhadern, GER
Conference Site

Centro de Congressos de Lisboa
Praça das Indústrias
1300-307 Lisboa
Portugal
+351 213 601 400/1
+351 213 639 450
lisboacc@aip.pt
www.lisboacc.pt

Scientific organizing committee:

Philippe Ruszniewski  Clichy  FRA
Guido Rindi    Rome  ITA
Kjell Öberg    Uppsala  SWE
Bertram Wiedenmann  Berlin  GER
Martyn Caplin    London  GBR
Dermot O’Toole    Dublin  IRL
Massimo Falconi    Verona  ITA
Beata Kos-Kudła  Katowice  POL
Ramon Salazar    Barcelona  ESP

Conference organization:

ENETS Coordinating Office
c/o Charité - University Hospital
Campus Virchow-Klinikum
Hepatology and Gastroenterology
Augustenburger Platz 1
13353 Berlin, Germany

Tel  +49 (0)30 450-553 096/-553 042
Fax  +49 (0)30 450-565 996

www.neuroendocrine.net
enets-annual-conference@charite.de
Mark Your Calendars Now!

9th Annual ENETS Conference

for the Diagnosis and Treatment of Neuroendocrine Tumors

For more information, visit: www.neuroendocrine.net

7-9 March 2012 • Copenhagen • Denmark
In treating advanced neuroendocrine tumors...

How do we overcome the lack of options?

Effective treatment is needed to fight this potentially aggressive disease

Advanced neuroendocrine tumors (NET) present a serious challenge. The median duration of survival among patients with metastatic NET is 33 months.¹

NET is a complex disease affecting many organ systems, NETs most commonly develop in the GI tract and lung, occurring in more than 85% of NET patients.² Although not as common, metastatic pancreatic NET can be aggressive, with a median survival time of only 27 months.³

Effective treatment strategies are needed to help improve progression-free survival in patients with advanced NET.

Even with today's treatment options, preventing tumor growth in advanced NET remains a major challenge and a significant concern for patients. For NET of GI, lung, or pancreatic origin, new approaches to treatment are needed.

For NET of GI, lung, or pancreatic origin, new approaches to treatment are needed.

To address this unmet need, Novartis Oncology has undertaken trials investigating patients with advanced neuroendocrine tumors who may or may not have been symptomatic at the time of enrollment.⁴ Novartis Oncology has a strong heritage of leadership in developing cancer therapies that have enriched and improved the lives of patients living with many types of cancer. We are dedicated to developing effective treatment options for patients with diverse types of advanced NET.

References: